KORU Medical Systems (NASDAQ:KRMD) Given New $8.00 Price Target at B. Riley Financial

KORU Medical Systems (NASDAQ:KRMD) had its target price hoisted by B. Riley Financial from $7.00 to $8.00 in a research report issued on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. B. Riley Financial’s target price would indicate a potential upside of 83.02% from the stock’s current price.

A number of other brokerages have also weighed in on KRMD. Wall Street Zen upgraded KORU Medical Systems from a “buy” rating to a “strong-buy” rating in a research note on Monday, January 12th. Craig Hallum restated a “buy” rating and issued a $7.00 price target on shares of KORU Medical Systems in a research note on Tuesday, January 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of KORU Medical Systems in a research report on Thursday, January 22nd. Canaccord Genuity Group increased their target price on shares of KORU Medical Systems from $5.00 to $6.00 and gave the stock a “buy” rating in a research report on Wednesday, December 17th. Finally, Lake Street Capital lifted their price target on shares of KORU Medical Systems from $6.00 to $8.00 and gave the company a “buy” rating in a research report on Monday, December 22nd. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $6.50.

KORU Medical Systems Stock Performance

KRMD stock traded up $0.06 during midday trading on Friday, reaching $4.37. 225,321 shares of the company were exchanged, compared to its average volume of 197,323. KORU Medical Systems has a one year low of $1.86 and a one year high of $6.61. The firm has a market capitalization of $202.46 million, a price-to-earnings ratio of -54.50 and a beta of 0.47. The business has a 50-day moving average price of $5.13 and a two-hundred day moving average price of $4.79. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.48 and a quick ratio of 1.92.

KORU Medical Systems (NASDAQ:KRMD) last posted its earnings results on Thursday, March 12th. The company reported ($0.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.01. KORU Medical Systems had a negative net margin of 9.49% and a negative return on equity of 22.43%. The company had revenue of $10.90 million during the quarter, compared to analysts’ expectations of $10.90 million. Equities research analysts forecast that KORU Medical Systems will post -0.13 EPS for the current year.

Institutional Investors Weigh In On KORU Medical Systems

Hedge funds have recently made changes to their positions in the stock. Invesco Ltd. lifted its stake in KORU Medical Systems by 24.8% in the 4th quarter. Invesco Ltd. now owns 27,873 shares of the company’s stock valued at $162,000 after purchasing an additional 5,546 shares during the last quarter. Occudo Quantitative Strategies LP acquired a new position in shares of KORU Medical Systems during the fourth quarter worth $127,000. Price T Rowe Associates Inc. MD increased its holdings in shares of KORU Medical Systems by 26.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 27,036 shares of the company’s stock worth $158,000 after buying an additional 5,649 shares in the last quarter. Russell Investments Group Ltd. lifted its stake in shares of KORU Medical Systems by 28.3% in the 4th quarter. Russell Investments Group Ltd. now owns 195,773 shares of the company’s stock valued at $1,137,000 after acquiring an additional 43,215 shares during the last quarter. Finally, Royal Bank of Canada boosted its holdings in shares of KORU Medical Systems by 8,719.9% during the 4th quarter. Royal Bank of Canada now owns 133,004 shares of the company’s stock valued at $773,000 after acquiring an additional 131,496 shares in the last quarter. 58.60% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting KORU Medical Systems

Here are the key news stories impacting KORU Medical Systems this week:

• Positive Sentiment: KORU reported fourth‑quarter revenue growth and a small EPS beat (Q4 EPS -$0.01 vs. consensus -$0.02) and matched revenue expectations, showing improvement vs. a year ago. This supports the stock’s upside today. KORU Medical Systems Inc. (KRMD) Reports Q4 Loss, Beats Revenue Estimates
• Positive Sentiment: The company announced ~20% revenue growth for Q4 and full‑year 2025, delivered positive adjusted EBITDA, and initiated FY‑2026 guidance (revenue range roughly $47.5M–$50.0M), giving investors a clearer near‑term outlook. KORU Medical Systems Announces +20% Fourth Quarter and Full Year 2025 Revenue Growth, Positive Adjusted EBITDA and Initiates Full Year 2026 Guidance
• Positive Sentiment: KORU received EU MDR certification for its Freedom60® infusion pump with prefilled syringe compatibility — a regulatory clearance that can support European commercialization and recurring revenue potential. KORU Medical Systems Announces EU MDR Certification for the Freedom60® Infusion Pump With Prefilled Syringe Compatibility
• Neutral Sentiment: KORU held its Q4 earnings call; the transcript provides details on growth drivers, product adoption, and margin trends for investors who want management color. KORU Medical Systems, Inc. (KRMD) Q4 2025 Earnings Call Transcript
• Neutral Sentiment: The company announced a CEO transition: longtime CEO Linda Tharby will retire effective June 30, 2026 and Adam Kalberma has been appointed. Leadership change adds execution risk uncertainty but also a planned succession. KORU Medical Systems Announces CEO Transition
• Negative Sentiment: Despite progress, KORU remains GAAP unprofitable (negative net margin ~9.5% and negative ROE) and posted a small per‑share loss; continued losses and modest scale could limit valuation expansion until profitability sustainably improves. Earnings release and financial details

KORU Medical Systems Company Profile

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products.